Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Aug;30(8):680-685.
doi: 10.5152/tjg.2019.18426.

Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease

Hua Fan  1 , Juan Du  2 , Xia Liu  1 , Wei-Wei Zheng  1 , Ze-Hao Zhuang  1 , Cheng-Dang Wang  1 , Rui Gao  1
Affiliations
Randomized Controlled Trial

Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease

Hua Fan et al. Turk J Gastroenterol. 2019 Aug.

Abstract

Background/aims: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probiotics on the microflora composition and prognosis in patients with inflammatory bowel disease (IBD).

Materials and methods: A total of 40 patients with IBD (19 control group and 21 observation group) were randomized. Patients in the control group were given pentasa, and patients in the observation group were given probiotics along with pentasa. The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed.

Results: After treatment, the number of enterobacteria, enterococci, saccharomyces, and bacteroides; the levels of fecal lactoferrin, 1-antitrypsin, β2-microglobulin, high-sensitivity C-reactive protein, and interleukin (IL)-6; activity scores; and recurrence rate in the observation group were significantly lower than those in the control group. Bifidobacterium and lactobacillus counts and IL-4 levels were significantly higher in the observation group than in the control group.

Conclusion: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level of inflammatory cytokines; therefore, it is worthy of further clinical validation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Changes in microflora composition at different stages in the two groups. The control group was given pentasa (1 tablet once and three times a day), and the observation group was given probiotics (2 tablets once and three times a day) along with pentasa. *p<0.05, **p<0.01.
Figure 2
Figure 2
Comparison of biochemical indices of both groups. The control group was given pentasa (1 tablet once and three times a day), and the observation group was given probiotics (2 tablets once and three times a day) along with pentasa. *p<0.05.
Figure 3
Figure 3
Comparison of inflammatory markers before and after treatment in the two groups. The control group was given pentasa (1 tablet once and three times a day), and the observation group was given probiotics (2 tablets once and three times a day) along with pentasa. *p<0.05.
See this image and copyright information in PMC

References

    1. Rhodes J, Thomas G, Evans BK. Inflammatory Bowel Disease Management. Drugs. 1997;53:189–94. doi: 10.2165/00003495-199753020-00001. - DOI - PubMed
    1. Zurek M, Kern I, Manuwald U, et al. Epidemiology and care structures for children and adolescents and young adults up to the 26th year of life with inflammatory bowel diseases (IBD) in Leipzig/Saxony/Germany. J Public Health. 2018:1–6. doi: 10.1007/s10389-017-0884-2. - DOI - PubMed
    1. Chadwick VS, Chen W. Medical Importance of the Normal Microflora. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1999. The intestinal microflora and inflammatory bowel disease; pp. 177–221. - DOI
    1. Bamias G, Pizarro T, Cominelli F. New Paradigms in the Pathogenesis of IBD. Inflamm Bowel Dis. 2011:41–57. doi: 10.1007/978-1-60327-433-3_4. - DOI - PubMed
    1. Dong X, Ye X, Chen X, et al. Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease. Dig Dis Sci. 2014;59:769–77. doi: 10.1007/s10620-013-2962-9. - DOI - PMC - PubMed

Publication types